Question explored with the scientific record
What are the risks of taking the shingles vaccibe
The shingles vaccine's main risk is a temporary but intense flu-like reaction; a rarer but real risk is Guillain-Barré syndrome, and the evidence for that comes from a manufacturer-funded analysis.
The most common risks are not subtle. In a 2026 analysis of nearly 70,000 US reports to VAERS, the most frequent complaints after Shingrix were fever (18.3%), body pain (17.8%), chills (15.9%), and headache (15.4%) [1]. Injection-site pain was reported disproportionately often compared to other vaccines [1]. These are transient, but they are common. A 2021 open-label study funded by GlaxoSmithKline found that 59.6% of participants reported an unsolicited adverse event within 30 days of a dose, and 50.9% were considered vaccination-related [4].
The more serious risk is Guillain-Barré syndrome (GBS). A 2022 review of a self-controlled case series found an attributable risk of about 3 extra GBS cases per million doses within 42 days of vaccination [2]. The same review notes this was a "statistical signal" that required further monitoring [2]. The 2026 VAERS analysis recorded 194 GBS reports in the herpes zoster vaccine cohort (0.28% of reports), but the authors correctly note this is a raw count, not an incidence, because VAERS has no denominator [1].
The evidence for benefit is strong in clinical trials but weaker in real-world use. The pivotal ZOE trials, funded by GSK, showed 97.2% efficacy against shingles in adults aged 50 and older [2]. But a large Medicare study found real-world effectiveness of only 70.1% after two doses [2]. The difference matters: trials are run on healthy volunteers, and real-world populations are older and sicker.
| Risk / Benefit | Shingrix (Recombinant) | Zostavax (Live, older) |
|---|---|---|
| Most common side effects | Fever, pain, chills, headache (~15-18% each) [1] | Injection-site reactions (~18.5%) [3] |
| Serious reports (proportion of VAERS reports) | 2.9% [1] | 27.6% [1] |
| Guillain-Barré signal | ~3 excess cases per million doses [2] | Not quantified in this retrieval |
| Vaccine efficacy (trial) | 97.2% [2] | 51.3% [2] |
| Vaccine effectiveness (real-world) | 70.1% [2] | ~46% [2] |
My call: the shingles vaccine has a high rate of temporary, unpleasant reactions and a small but documented risk of GBS. The benefit in preventing shingles is real but lower in real-world use than in trials. The evidence base is dominated by manufacturer-funded studies, and the long-term safety data beyond a decade is thin. Confidence: moderate.
Sources used 4
-
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…
DOI: 10.3389/fmed.2026.1920596 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
This study provides a comprehensive review of the post-marketing safety experience of the herpes zoster vaccine (ZVL) over a 10-year period, analyzing over 23,000 adverse experience reports and confirming a favorable safety profile consistent with clinical trial data.
DOI: 10.1016/j.vaccine.2017.11.013 -
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029